Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Pediatric Subjects 6 to <12 Years Old With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

NCT07896434 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07896434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Pediatric Subjects 6 to <12 Years Old With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 28, 2027
Completion date
August 31, 2032
Enrollment
154 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-segmental vitiligo

Arms

As registered; 2 arms.

  • Period A: Double-Blind Treatment Period ExperimentalPlacebo for Upadacitinib, Upadacitinib

    Pediatric participants will receive an adult-equivalent dose of upadacitinib or a matching placebo dose

  • Period B: Blinded Extension Period ExperimentalPlacebo for Upadacitinib, Upadacitinib

    Pediatric participants who complete Period A will continue into Period B and remain on blinded treatment.

    Pediatric participants initially randomized to blinded placebo (Period A) who have not achieved F-VASI 75 at Week 48 (nonresponders) will receive a blinded upadacitinib adult dose equivalent in Period B.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (>= 75% Improvement in F-VASI From Baseline) At Week 48

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.

  • Number of Participants with Adverse Events (AEs) Up to Approximately Day 1150

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Lead sponsor's other trials

AbbVie, most recent start first.